OBAT
OLEH:
NELLA NOVITA
2121012021
[1] Melo, K.J.C., Henostroza, M.A.B., and Lobenberg, R. et al., Rifampicin nanocrystals:
Towards an innovative approach to treat tuberculosis, Materials Science & Engineering C
(2020), https://doi.org/10.1016/j.msec.2020.110895
[2] Yalkowsky, S.H., He, Yan., Handbook of Aqueous Solubility Data: An Extensive
Compilation of Aqueous Solubility Data for Organic Compounds Extracted from the AQUASOL
dATAbASE. CRC Press LLC, Boca Raton, FL. (2003)., p. 1261
[3] Van Ingen, J., Aarnoutse, R.E., Donald, P.R., Diacon, A.H., Dawson, R., Plemper van Balen,
G., Gillespie, S.H., Boeree, M.J. Why do we use 600 mg of rifampicin in tuberculosis treatment?
Clin. Infect Dis. 52, (2011), e194–199.
[4] Suciati, T., Istiqomah, N., Permana, B., Julianti, E., Yudistira, T., Wibowo, M.S., and
Triyani, Y. Formula Optimization of NLC with D-Mannose Targeting for Rifampicin Delivery
System. Jurnal Ilmu Kefarmasian Indonesia, Vol. 17, No. 2(2019), p. 189-198.
https://doi.org/10.1016/j.ijpharm.2018.07.011
[5] Surini, S., Providya, R., and Putri, K.S.S. Formula Optimization of Rifampicin Dry Powder
Inhalation with Chitosan-Xanthan Carrier Using Response Surface Methodology. Journal of
Applied Pharmaceutical Science, (2019), Vol. 9(01), pp 033-041. DOI:
10.7324/JAPS.2019.90106
[6] Zhou, Q., Leung, S.S.Y., Tang, P., Parumasivam, T., Loh, Z.H., and Chan, H.K. Inhaled
formulations and pulmonary drug delivery systems for respiratory infections. Advanced Drug
Delivery Reviews, (2014), p. 85; 83–99.
[7] Changsan, N., Chan, H.K., Separovic, F., and Srichana, T. Physicochemical Characterization
and Stability of Rifampicin Liposome Dry Powder Formulations for Inhalation. Journal Of
Pharmaceutical Sciences, Vol. 98, No. 2, February (2009).
[8] Khadka, P., Dummer, J., Hill, P. C., and Das, S. C. Considerations in preparing for clinical
studies of inhaled rifampicin to enhance tuberculosis treatment. International Journal of
Pharmaceutics 548 (2018), p. 244-254.
[9] Mistry, N., Bandyopadhyaya, R., and Mehra, S. ZnO Nanoparticles and Rifampicin
Synergistically Damage the Membrane of Mycobacteria. ACS Applied Nano Materials, (2020).
DOI: 10.1021/acsanm.9b02089
[10] Jaafar-Maalej, C., Elaissari, A., Fessi, H. Lipid-based carriers: manufacturing and
applications for pulmonary route. Expert Opin. Drug Deliv. 9, (2012), 1111–1127.
[11] Misra, A., Hickey, A.J., Rossi, C., Borchard, G., Terada, H., Makino, K., Fourie, P.B.,
Colombo, P. Inhaled drug therapy for treatment of tuberculosis. Tuberculosis (Edinb) 91, (2011),
71–81.